Page 14 - Mylan EpiPen
P. 14
times Mylan’s overall tax rate for 2015. Profit was probably
about 60% higher than that declared.
Lauren Kashtan a
spokeswoman for Mylan
insisted the EpiPen is a complex
prescription product, with more
than 15 critical component
parts that must work every time
without fail in an emergency
situation, it’s not something that
can be made in a garage.
Bresch also maintained that the
company had spent hundreds
of millions of dollars improving
the product since buying the
product from Merck in 2007.
She also blamed the complex US health care system for the
price. Members of Congress however, required Bresch to
disclose her salary for the year 2015 - $19m.
